FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

BMC Cancer

Table 3 Tumor Response and Survival

	No. of Patients (%)
Tumor response
Complete response	0 (0.0)
Partial response	0 (0.0)
Stable disease	8 (36.4)
Progression disease	14 (63.6)
Median progression free survival (months) [95% CI]	1.7 [1.0 - 2.5]
Median overall survival (months) [95% CI]	4.3 [2.2 - 5.9]

Tumor response was evaluated in 22 patients among the 27 patients included. Evaluation could not be performed for 4 patients because of early death and for 1 patient because of limiting toxicity after two cycles.

ISSN: 1471-2407